Late-Stage Obesity Pipeline Is Stuffed With Mix Of Mechanisms
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Takeda/Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Development of a once-promising combination of pramlintide and metreleptin for obesity has been discontinued after a "commercial reassessment," U.S.-based Amylin Pharmaceuticals Inc. and Japan's Takeda Pharmaceutical Company Limited announced Aug. 4
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."